company background image
ET8 logo

COSCIENS Biopharma DB:ET8 Stock Report

Last Price

€2.88

Market Cap

€10.9m

7D

-2.0%

1Y

-51.4%

Updated

18 Nov, 2024

Data

Company Financials

ET8 Stock Overview

A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. More details

ET8 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

COSCIENS Biopharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for COSCIENS Biopharma
Historical stock prices
Current Share PriceCA$2.88
52 Week HighCA$9.36
52 Week LowCA$2.42
Beta2.26
11 Month Change-10.56%
3 Month Change-42.28%
1 Year Change-51.35%
33 Year Change-93.41%
5 Year Change-96.48%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

ET8DE BiotechsDE Market
7D-2.0%-0.02%-1.5%
1Y-51.4%-17.7%7.9%

Return vs Industry: ET8 underperformed the German Biotechs industry which returned -16.7% over the past year.

Return vs Market: ET8 underperformed the German Market which returned 8.3% over the past year.

Price Volatility

Is ET8's price volatile compared to industry and market?
ET8 volatility
ET8 Average Weekly Movement19.9%
Biotechs Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ET8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: ET8's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1990n/aGilles Gagnonwww.cosciensbio.com

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.

COSCIENS Biopharma Inc. Fundamentals Summary

How do COSCIENS Biopharma's earnings and revenue compare to its market cap?
ET8 fundamental statistics
Market cap€10.87m
Earnings (TTM)-€22.05m
Revenue (TTM)€4.59m

2.3x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ET8 income statement (TTM)
RevenueUS$4.83m
Cost of RevenueUS$668.00k
Gross ProfitUS$4.17m
Other ExpensesUS$27.38m
Earnings-US$23.21m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-6.28
Gross Margin86.18%
Net Profit Margin-480.12%
Debt/Equity Ratio0%

How did ET8 perform over the long term?

See historical performance and comparison